https://www.onclive.com/conference-coverage/gu-2017/dr-jonasch-on-promise-of-immunooncology-agents-in-rcc
Dr. Jonasch on Promise of Immuno-Oncology Agents in RCC

Eric Jonasch, MD



Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the promise of immuno-oncology agents in sarcomatoid renal cell carinoma (RCC).

Sarcomatoid RCC is a difficult disease in regard to efficacy, says Jonasch. But, with studies stating that PD-L1 expression in RCC is high, the use of checkpoint antibodies could be promising.

Jonasch says that this high expression of PD-L1 supports the hypothesis that, if targeted, checkpoint antibodies could be succesful in treatment of patients with the disease.
 
Printer Printing...